BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
Targeting Glioblastoma with Multifunctional Anti-RAGE Oligonucleotides
Targeting Glioblastoma with Multifunctional Anti-RAGE Oligonucleotides is a funding opportunity from BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, up to 548395, closing April 30, 2031.
Apr 30, 2031
(1734d left)Overview
PROJECT SUMMARY Patients diagnosed with glioblastoma (GBM) have a median overall survival of less than two years even after receiving multimodal therapies. Multiple factors account for treatment resistance including: 1) Inability of therapies to cross the blood-brain barrier to reach invading cells; 2) GBM’s…